Human dental pulp stem cells protect mouse dopaminergic neurons against MPP+ or rotenone

Nesti, Claudia; Pardini, Carla; Barachini, Serena; D’Alessandro, Delfo; Siciliano, Gabriele; Murri, Luigi; Petrini, Mario; Vaglini, Francesca

doi:10.1016/j.brainres.2010.09.042

Cited by 52 publications

(56 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MPP + (Sigma-Aldrich, USA) was added 1 h following TGF-b1 application at a concentration of 5 lM, as described by Nesti et al (2011). They were incubated for 24 h and then assessed for DAergic neuronal loss and inflammatory responses.…”

Section: Drug Treatmentmentioning

confidence: 99%

Transforming growth factor-β1 acts via TβR-I on microglia to protect against MPP+-induced dopaminergic neuronal loss

Chen

Huang

et al. 2016

Brain, Behavior, and Immunity

View full text Add to dashboard Cite

Section: Drug Treatmentmentioning

confidence: 99%

Transforming growth factor-β1 acts via TβR-I on microglia to protect against MPP+-induced dopaminergic neuronal loss

Chen

Huang

et al. 2016

Brain, Behavior, and Immunity

View full text Add to dashboard Cite

“…Nesti et al 89 investigated the neuroprotective effects of DPSC against MPP+ and rotenone in an in vitro model of Parkinson’s disease, using an indirect co-culture system with mesencephalic cell cultures. They found that the co-culture with DPSCs significantly attenuated MPP+ or rotenone-induced toxicity probably by the neuroprotection by the soluble factors such as BDNF and NGF, released by DPSC.…”

Section: Neurological Disordersmentioning

confidence: 99%

Therapeutic potential of dental stem cells

et al. 2017

View full text Add to dashboard Cite

Stem cell biology has become an important field in regenerative medicine and tissue engineering therapy since the discovery and characterization of mesenchymal stem cells. Stem cell populations have also been isolated from human dental tissues, including dental pulp stem cells, stem cells from human exfoliated deciduous teeth, stem cells from apical papilla, dental follicle progenitor cells, and periodontal ligament stem cells. Dental stem cells are relatively easily obtainable and exhibit high plasticity and multipotential capabilities. The dental stem cells represent a gold standard for neural-crest-derived bone reconstruction in humans and can be used for the repair of body defects in low-risk autologous therapeutic strategies. The bioengineering technologies developed for tooth regeneration will make substantial contributions to understand the developmental process and will encourage future organ replacement by regenerative therapies in a wide variety of organs such as the liver, kidney, and heart. The concept of developing tooth banking and preservation of dental stem cells is promising. Further research in the area has the potential to herald a new dawn in effective treatment of notoriously difficult diseases which could prove highly beneficial to mankind in the long run.

show abstract

“…Some of these oral/dental stem cells have shown the abilities of neural differentiation and neuroprotection, hence have great potential for treating neurodegenerative diseases [63]. For example, Nesti and colleagues have found the co-culture with DPSCs significantly attenuated MPP+ or rotenone-induced toxicity in primary cultures of mesencephalic neurons, presumably due to soluble factors such as BDNF and NGF released by DPSCs [64]. Later, it has been demonstrated that some soluble factors involved in the development of DA neurons induced a DA phenotype in human oral mucosa stem cells (hOMSCs) in vitro that significantly improved the motor function of hemiparkinsonian rats.…”

Section: Mesenchymal Stem Cells (Mscs)mentioning

confidence: 99%

Development of stem cell-based therapies for Parkinson's disease

Zhu

Caldwell

Song

2016

International Journal of Neuroscience

View full text Add to dashboard Cite

I.Abstract Parkinson's disease (PD) is a common neurodegenerative disorder characterized by the progressive loss of dopaminergic neurons of the substantia nigra pars compacta (SNpc) in the brain with an unknown cause. Current pharmacological treatments for PD are only symptomatic and there is still no cure for this disease nowadays. In fact, transplantation of human fetal ventral midbrain cells into PD brains have provided a proof of concept that cell replacement therapy can be used for some PD patients, beneficial for improving their symptoms. However, the ethical and practical issues of human fetal tissue will inevitably limit its widespread clinical use. Therefore, it is essential to find alternative cell sources for the future cell transplantation for PD patients. With recent development in stem cell technology, here we review the different types of stem cells and their main properties currently explored, which could be developed as a possible cell therapy for PD treatment.

show abstract

Human dental pulp stem cells protect mouse dopaminergic neurons against MPP+ or rotenone

Cited by 52 publications

References 32 publications

Transforming growth factor-β1 acts via TβR-I on microglia to protect against MPP+-induced dopaminergic neuronal loss

Transforming growth factor-β1 acts via TβR-I on microglia to protect against MPP+-induced dopaminergic neuronal loss

Therapeutic potential of dental stem cells

Development of stem cell-based therapies for Parkinson's disease

Contact Info

Product

Resources

About